The Latest

  • A thumbnail illustration for BioPharma Blog's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Blog
    Image attribution tooltip
    Deep Dive

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Including Contineum’s IPO, biotechs have now raised about $1.43 billion in new stock offerings this year, nearly quadrupling last year’s total by this point.

    Updated April 5, 2024
  • Cleanroom image
    Image attribution tooltip
    Permission granted by PHC Corporation of North America
    Image attribution tooltip
    Sponsored by PHC Corporation of North America (PHCNA)

    Keeping cleanrooms clean: Choosing the right laboratory equipment is key

    Because live cell and tissue products are sensitive to contamination from microorganisms, viral particles or other impurities, research and manufacturing involving these materials needs to be conducted in a cleanroom environment.

  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex begins bid for US approval of non-opioid painkiller

    The biotech has begun a rolling submission of a closely watched drug that’s important to its future, but faces questions of sales potential.

    FDA
  • Anne Wojcicki speaking event
    Image attribution tooltip
    Brad Barket via Getty Images
    Image attribution tooltip

    23andMe CEO plans to take company private

    Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly obesity drug shows benefit in sleep disorder study, pointing to new use

    Positive data for Lilly’s medicine tirzepatide in sleep apnea are the latest signal the benefits of GLP-1 agonists could extend beyond diabetes and weight loss.

  • An illustration of two neurons, colored blue and purple
    Image attribution tooltip
    noparrit via Getty Images
    Image attribution tooltip

    Sage’s cognition drug fails in Parkinson’s study

    Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.

  • An illustration for BioPharma Blog's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Blog
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Vertex’s proposed buyout of Alpine Immune Sciences is the largest biotech acquisition to be announced so far this year.

    Updated April 10, 2024
  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip

    Stelara biosimilar from Alvotech, Teva approved by FDA

    The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.

  • A portrait of Uwe Schoenbeck at Canaan Partners.
    Image attribution tooltip
    Permission granted by Canaan
    Image attribution tooltip

    Canaan hires Pfizer executive, reels in $100M for biotech investing

    The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.

  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J sees mixed performance from new multiple myeloma drugs

    Tecvayli sales, which J&J broke out for the first time, surpassed Wall Street forecasts and offset underperformance from Carvykti, which J&J attributed to the "phasing and timing of orders."

  • An illustration of a brain disintegrating
    Image attribution tooltip
    Eoneren via Getty Images
    Image attribution tooltip

    Intra-Cellular builds case for depression drug with late-stage trial win

    Shares of the biotech rose 25% after a large trial found adding its drug Caplyta onto antidepressant therapy significantly helped people with major depression.

  • An illustration of antibodies attacking a nerve cell.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Cullinan changes name, pivots to autoimmune disease

    The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.

  • Regeneron commits $500M to new venture capital fund

    While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.

  • Neumora CEO Henry Gosebruch stands for a photo against a blurred office background
    Image attribution tooltip
    Permission granted by Neumora Therapeutics
    Image attribution tooltip

    Neumora’s schizophrenia drug hit with clinical hold

    Shares of the biotech dipped by double digits following disclosure the FDA had paused an early-stage study of Neumora’s muscarinic-targeting drug.

  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Roche reports survival data for new dual-acting lymphoma drug

    The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.

  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Image attribution tooltip

    Ultragenyx says Angelman therapy is working, but safety questions remain

    Treatment appeared to result in functional and cognitive gains in people with the neurological disorder. Three participants experienced lower extremity weakness, however.

  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Biotech IPOs bounced back in first quarter, but backlog remains

    Proceeds from biotech IPOs during the first three months of 2024 matched levels seen in the first quarters of 2019 and 2020, BioPharma Blog data show.

  • Boxes of the diabetes drug Ozempic rest on a pharmacy counter.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    European regulator concludes no suicide link to obesity drugs

    The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.

  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Nemes Laszlo via Getty Images
    Image attribution tooltip

    Roche, Adaptimmune part ways on cell therapy research

    The two companies have ended a collaboration that was struck in 2021 and focused on “off-the-shelf” cell therapies for cancer.

  • A photo of Regeneron's Tarrytown, NY headquarters.
    Image attribution tooltip
    Regeneron
    Image attribution tooltip

    US sues Regeneron, alleging false price reporting on Eylea

    The lawsuit claims the drugmaker didn’t disclose reimbursement to drug distributors for credit card fees, artificially inflating the reported price of the blockbuster eye drug.

  • Vertex CEO Reshma Kewalramani
    Image attribution tooltip
    Permission granted by Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex to buy kidney disease drugmaker Alpine for $4.9B

    A proposed $4.9 billion buyout of Alpine Immune Sciences would be the largest ever acquisition for Vertex and align with its "toolkit of technologies" approach to dealmaking.

    Updated April 11, 2024
  • NK Cell (Natural Killer Cell) Attacking a Cancer Cell
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Emerging biotech

    Century buys a startup, raises funding in cell therapy expansion

    The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.

  • A pregnant person is checked with a stethoscope in a doctor's office.
    Image attribution tooltip
    PeopleImages via Getty Images
    Image attribution tooltip

    J&J, Rallybio partner on drug development for rare fetal condition

    The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis pauses enrollment in some Kisqali trials to fix manufacturing

    The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.

  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip
    RSV vaccines

    Pfizer, with new study results, seeks to bring RSV shot to adults aged 18-59

    The company plans to submit the trial data to regulators in a bid to win approval of its vaccine Abrysvo in adults as young as 18 years old.

  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    whitehoune via Getty Images
    Image attribution tooltip
    Emerging biotech

    PureTech launches Seaport, hoping to create Karuna 2.0

    The startup is taking aim at anxiety with $100 million from high-profile biotech backers like ARCH, Sofinnova and Third Rock.